Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, May 23, 2019

1:00 p.m. – 5:00 p.m.

DXC Building, 4070 27th Ct

Salem, OR 97301

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Tracy Klein, PhD, FNP; Caryn Mickelson, PharmD; Mark Helm, MD, MBA, FAAP; Russell Huffman, DNP, PMHNP; William Origer, MD; Cathy Zehrung, RPh

Members Present by Phone: Kelley Burnett, DO; David Pass, MD**;** Stacy Ramirez, PharmD; James Slater, PharmD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Richard Holsapple, RPh; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Renae Wentz, MD; Dee Weston; Trevor Douglass, DC, MPH; Brandon Wells; Jennifer Torkelson; Michelle Hatfield; Joelle Ayoub, PharmD

Staff Present by Phone:

Audience: Rick Frees, Vertex; Tim McFerrin, Alkermes; Roy Lindfield; Craig Sexton, GSK; *Anthony Wheeler, Lilly; Rebecca Cashner, OSU/OHSU COP; Venus Holder, Lilly; Jeremy Strand, Alexion; Melanie Lamarche, Merck; Geetika Gupta, Merck; Lisa Boyle, WVP Health; Steve Isaki, Lundbeck; Mae Kwong, Janssen; Doug Buriani, SOBI; Maggi Olmon, AbbVie; Donna Tehrani; Mayra Barrera; Laura Jeffcoat, AbbVie; Danielle Shannon, WVP Health; *Maria Agapova, Teva; Diann Matthews, Merz; Christian Johnson

(*) Provided verbal testimony

Written testimony provided: Posted to OSU Website

I. CALL TO ORDER

A. Roll Call & Introductions
B. Conflict of Interest Declaration
C. Approval of Agenda and Minutes
ACTION: Motion to approve, 2nd, all in favor
D. Department Update: Trevor Douglass, staffing updates
E. Legislative Update: Trevor Douglass reviewed agency policy during legislative session regarding discussion of active bills. Reviewed: HB2692- passed & signed, HB2678 to Ways & Means, and HB3397

II. CONSENT AGENDA TOPICS

A. Quarterly Utilization Reports
ACTION: Motion to approve, 2nd, all in favor

III. DUR ACTIVIES

A. ProDUR Report - Mr. Holsapple presented the ProDUR report
B. RetroDUR Report - Dr. Engen presented the RetroDUR report
C. Oregon State Drug Reviews
1. 2017-2018 Year in Review: Important Safety Updates
2. Benzodiazepine Safety and Tapering
Dr. Sentena presented two recently published newsletters, thanked the Committee for reviewing the draft versions and solicited ideas for future newsletters

IV. DUR OLD BUSINESS 1:35 PM

A. GnRH Modifiers
Mr. Citron presented the proposal to:
1. Add the class to the PMPDP and designate all agents as non-preferred

ACTION: Motion to approve, 2nd, all in favor

B. Combination Biologic Therapy Drug Use Evaluation
Dr. Servid presented the proposal to:
1. Update PA criteria to include a maximum dose for patients with rheumatoid arthritis prescribed tofacitinib and to reinforce periodic tuberculosis testing

ACTION: Update Renewal criteria #3 to reference prescribing provider rather than prescribing physician and develop a RetroDUR provider education on DMARD adherence after 3 months
Motion to approve, 2nd, all in favor

V. DUR NEW BUSINESS

A. Attention Deficit Hyperactivity Disorder Drug Use Evaluation
Dr. Ayoub presented the proposal to:
1. Continue to monitor use of ADHD medications
2. Consider provider education on importance of diagnosis and assessment for patients with treatment-resistant ADHD symptoms and those at an increased risk of substance misuse

Action: Develop RetroDUR to evaluate combination of stimulant and antipsychotic medications
Motion to approve, 2nd all in favor

B. Adherence Monitoring in Schizophrenia Patients
Dr. Servid presented the proposal to:
1. Recommend implementation of a retrospective initiative to notify providers when patients on routine therapy for schizophrenia miss a medication refill

ACTION: Modify proposed letter to streamline message and explore transitions of care opportunities for patients with denials based on lost Medicaid eligibility
Motion to approve, 2nd all in favor

VI. PREFERRED DRUG LIST NEW BUSINESS

A. Asthma/COPD Class Update and New Drug Evaluation
Dr. Sentena presented the proposal to:
1. Recommend clerical revisions to prior authorization (PA) criteria to remove references to guideline classifications of COPD
2. Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

B. Migraine Treatment and Prevention DERP Summary
Dr. Sentena presented the proposal to:
1. No changes to the PDL are recommended based on review of the evidence
2. Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

C. CGRP Inhibitors DERP Summary
Dr. Engen presented the proposal to:

1. No changes to the PDL are recommended based on review of the evidence
2. Evaluate costs in executive session

ACTION: Change duration of approval for renewal criteria to 6 months
Motion to approve, 2nd, all in favor

D. Potassium Exchangers Class Update and New Drug Evaluation
Dr. Moretz presented the proposal to:
1. Add sodium zirconium cyclosilicate to patiromer PA criteria to insure appropriate utilization for FDA-approved indications
2. Remove requirement for trial and failure of kayexlate because of the acute indication for kayexlate and black box warning
3. Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

E. Other Dyslipidemia Drugs Class Update
Dr. Herink presented the proposal to:
1. Update PA criteria to be consistent with the new evidence for use of non-statins to prevent ASCVD events
2. Consider retiring the PA criteria for lomitapide and mipomersen due to no utilization
3. Make gemfibrozil non-preferred due to safety concerns with use in combination with statin therapy
4. Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

VII. EXECUTIVE SESSION

Members Present: Mark Helm, MD, MBA, FAAP; Russell Huffman, DNP, PMHNP, Tracy Klein, PhD, FNP; William Origer, MD; Cathy Zehrung, RPh

Members Present by Phone: Stacy Ramirez, PharmD; James Slater, PharmD; David Pass, MD

Staff Present: Roger Citron, RPh; David Engen, PharmD, CGP; Richard Holsapple, RPh; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Renae Wentz, MD; Trevor Douglass, DC, MPH; Brandon Wells; Jennifer Torkelson; Michelle Hatfield; Joelle Ayoub

VIII. RECONVENE for PUBLIC RECOMMENDATIONS

A. Asthma/COPD Class Update and New Drug Evaluation
Recommendation: **Make Dulera, Tudorza, and Asmanex to preferred**

ACTION: Motion to approve, 2nd all in favor

B. Migraine Treatment and Prevention DERP Summary
Recommendation: **Make sumatriptan succinate syringe and zolmitriptan tablets, rapid tablets and nasal spray preferred**

ACTION: Motion to approve, 2nd all in favor

C. CGRP Inhibitors DERP Summary
Recommendation: **Make all agents in the class non-preferred**

ACTION: Motion to approve, 2nd all in favor:

D. Potassium Exchangers Class Update and New Drug Evaluation
Recommendation: **Make patiromer and maintain sodium zirconium cyclosilicate as non-preferred**

ACTION: Motion to approve, 2nd all in favor

E. Other Dyslipidemia Drugs Class Update
Recommendation: **Make ezetimibe and evolocumab preferred**

ACTION: Motion to approve, 2nd all in favor:

X. ADJOURN